Mitocurcumin

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Department of Atomic Energy, Government of India and 1 more

Model organisms1

Outcomes

Organismal bloating

downin flies1

1 study

Mitocurcumin decreases organismal bloating in flies.
“Mitocurcumin alleviates tumor-associated organismal bloating”
Model organismsin a Yorkie-driven intestinal stem cell tumor model
Mitocurcumin mediated redox disruption and metabolic rewiring induces tumor regression in Drosophila intestinal stem cell tumors
bioRxiv28 Aug 2026Preprint

Apoptosis

upin flies1

1 study

Mitocurcumin induces apoptosis in flies.
“enhances apoptosis in the tumor-bearing guts”
Model organismsin tumor-bearing guts
Mitocurcumin mediated redox disruption and metabolic rewiring induces tumor regression in Drosophila intestinal stem cell tumors
bioRxiv28 Aug 2026Preprint

Latest

1 in 12 months

bioRxiv28 Aug

Mitocurcumin mediated redox disruption and metabolic rewiring induces tumor regression in Drosophila intestinal stem cell tumors

Preprint: experiments in fliesGut and microbiome

Paper

Mitocurcumin

Outcomes

Latest

Mitocurcumin mediated redox disruption and metabolic rewiring induces tumor regression in Drosophila intestinal stem cell tumors

Related